Jason Harris

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Low diastolic blood pressure may harm the myocardium, which could lead to coronary heart disease.

Long-term dual antiplatelet therapy was associated with reduced MACE in patients who underwent complex percutaneous coronary intervention.

Patients with a history of atrial fibrillation were more likely to have postprocedural bleeding, blood transfusion, heart failure, cardiogenic shock, and in-hospital mortality.

Specificity, or less overtreatment, increased from 15% to 25% for both coronary heart disease and cardiovascular disease

Patients with heart failure or less-frequent angina were most likely to have their condition under-recognized.

Rate of thrombocytopenia was significantly higher for patients assigned to phosphate-buffered tirofiban, but not those assigned to unfractionated heparin or citrate-buffered tirofiban.

No reduction in cardiovascular morbidity or mortality at 30-day and 3-year follow-up.

Freedom from clinically driven target lesion revascularization was 96% at 6, 12, and 24 months with bioresorbable scaffold implantation below the knee.

Tri-ventricular pacing demonstrated a similar safety profile as bi-ventricular pacing.